GTC Biotherapeutics (fka GTCB)

[geneinvest]

Can anyone comment on the relevance of the below mentioned references in regards to the use of atryn in DIC?

Levi M and ten Cate H. Disseminated intravascular coagulation. N Eng J Med 1999; 341: 586-592.

Bernard GR et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Eng J Med 2001; 344: 699-709.

Derhaschnig U, Reiter R, Knöbel P Baumgartner M, Keen P, Jilma B. Recombinant human acti-vated protein C (rh APC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 2003; 102: 2093-8.

Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001; 29 (Suppl): S90-4.

Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N Eng J Med 2002; 347: 1030-34.

Warren HS, Suffredini AF, Eichacker PQ Munford RS. Risk and benefits of activated protein C treatment for severe sepsis. N Eng J Med 2002; 347: 1027-30.